Very happy with these recent staffing developments
Post# of 148178
(Total Views: 426)
Posted On: 03/13/2020 11:42:43 AM
Very happy with these recent staffing developments, but I guess I'm a bit confused about the end game.
I'm new here, so pardon my ignorance.
Dr. Patterson has done an excellent job making important introductions, participating in investor calls, lending his credentials to CYDY, attending FDA meetings, and generally being the Explainer-in-Chief. But, he has his own company, IncellDx.
And, IncellDx has an exclusive worldwide licensing agreement to buy non-commercial grade quantities of PA-14 or PRO 140 for use in the development and commercialization of immunoassays for quantitative measurement of CCR5 levels on human cells.
Link = https://www.cytodyn.com/investors/news-events...-agreement
Dr. Lalezari has served as a leading clinician for CytoDyn’s HIV and mTNBC trials with leronlimab. He, too, has excellent credentials. However, he is only being named the Interim Chief Medical Officer, and he is currently Chief Executive Officer and Director of Quest Clinical Research in San Francisco and has served as a principal investigator for Phase I, II, and III clinical studies of new therapies for viral diseases including HIV/AIDS, CMV, HPV, HSV, Hepatitis B &C, Influenza, RSV and cancer.
Link = https://www.cytodyn.com/investors/news-events...erim-chief
So we have two excellent advisers, who I assume are being compensated for their efforts -- but neither currently seems to be in the position to actually join the company on a full time basis.
Is it possible that Dr. Patterson needs to refocus his attention on his own company, and Dr. Lalezari is stepping in only on an interim basis to take on some of the many roles Dr. Patterson served?
Conversely, does a company with the potential opportunities that CytoDyn has (Rhetorical Question: Is there another one in the world?) not need an individual like Dr. Patterson or Dr. Lalezari operating on a full time basis?
And lastly, if CYDY somehow does not need such an individual working on a full time basis, does that somehow speak the 'exit strategy' envisioned by the BoD?
I'm new here, so pardon my ignorance.
Dr. Patterson has done an excellent job making important introductions, participating in investor calls, lending his credentials to CYDY, attending FDA meetings, and generally being the Explainer-in-Chief. But, he has his own company, IncellDx.
And, IncellDx has an exclusive worldwide licensing agreement to buy non-commercial grade quantities of PA-14 or PRO 140 for use in the development and commercialization of immunoassays for quantitative measurement of CCR5 levels on human cells.
Link = https://www.cytodyn.com/investors/news-events...-agreement
Dr. Lalezari has served as a leading clinician for CytoDyn’s HIV and mTNBC trials with leronlimab. He, too, has excellent credentials. However, he is only being named the Interim Chief Medical Officer, and he is currently Chief Executive Officer and Director of Quest Clinical Research in San Francisco and has served as a principal investigator for Phase I, II, and III clinical studies of new therapies for viral diseases including HIV/AIDS, CMV, HPV, HSV, Hepatitis B &C, Influenza, RSV and cancer.
Link = https://www.cytodyn.com/investors/news-events...erim-chief
So we have two excellent advisers, who I assume are being compensated for their efforts -- but neither currently seems to be in the position to actually join the company on a full time basis.
Is it possible that Dr. Patterson needs to refocus his attention on his own company, and Dr. Lalezari is stepping in only on an interim basis to take on some of the many roles Dr. Patterson served?
Conversely, does a company with the potential opportunities that CytoDyn has (Rhetorical Question: Is there another one in the world?) not need an individual like Dr. Patterson or Dr. Lalezari operating on a full time basis?
And lastly, if CYDY somehow does not need such an individual working on a full time basis, does that somehow speak the 'exit strategy' envisioned by the BoD?
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼